Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer.

By Ricky A. Sharma, Heather R. McLelland, Kirsti A. Hill, C. Ireson, Stephanie A. Euden, M. Manson, M. Pirmohamed, L. Marnett, A. Gescher, W. Steward. Clinical Cancer Research, 2001

860 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/d82f7dac457e5a0f9459f5d8ad87b652f39af005

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Targets of curcumin (2011, background): “This finding is consistent with other data shown in preclinical models [255-257] and in humans [245,249,251,253].”
Curcumin: An Anti-Inflammatory Molecule from a Curry Spice on the Path to Cancer Treatment (2011, background): “No evidence of clinical toxicity attributable to the extract was detected, however, no evidence of detectable systemic bioavailability was observed either [48].”
Curcumin as "Curecumin": from kitchen to clinic. (2008, background): “[160] assessed the pharmacodynamics and pharmacokinetics of a novel encapsulated turmeric extract administered at”
Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases (2017, background): “…oxide levels Ghalaut et al., 2012 Colorectal 220 mg·day 1; 29 daysa 15 Inhibited basal and LPS-induced PGE2 Plummer et al., 2001 2.2 g·day 1c; 4 months 15 Well tolerated Sharma et al., 2001 0.45, 3.6 g·day 1; 4 months 15 Well tolerated and efficacious Sharma et al., 2004 0.45, 1.8, 3.6 mg·day 1;…”
Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. (2002, background): “Curcumin sulfate is the first curcumin metabolite that has been identified in human feces (19), and its generation may have been catalyzed by these enzymes in the gut.”
Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. (2009, methodology): “in one taking 880 mg and one taking 1,320 mg for four months.(62) In the second trial, researchers used a higher potency curcuminoid preparation, each capsule containing 450 mg curcumin, 40 mg demethoxycurcumin, and 10 mg bisdemethoxycurcumin.”
Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy (2007, background): “Equally important, free curcumin was shown not to be cytotoxic to normal cells, including hepatocytes, mammary epithelial cells, kidney epithelial cells, lymphocytes, and fibroblasts at the dosages required for therapeutic efficacy against cancer cell lines [42-46]; these in vitro findings are under”